EA202191589A1 - Пероральная фармацевтическая композиция с растительным алкалоидом для лечения зависимостей - Google Patents

Пероральная фармацевтическая композиция с растительным алкалоидом для лечения зависимостей

Info

Publication number
EA202191589A1
EA202191589A1 EA202191589A EA202191589A EA202191589A1 EA 202191589 A1 EA202191589 A1 EA 202191589A1 EA 202191589 A EA202191589 A EA 202191589A EA 202191589 A EA202191589 A EA 202191589A EA 202191589 A1 EA202191589 A1 EA 202191589A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
alkaloid
pharmaceutical composition
oral
present
Prior art date
Application number
EA202191589A
Other languages
English (en)
Inventor
Ангел Алексиев Алексиев
Веселин Евгениев Даскалов
Original Assignee
Софарма Ад
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Софарма Ад filed Critical Софарма Ад
Publication of EA202191589A1 publication Critical patent/EA202191589A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к пероральной фармацевтической композиции, которая содержит холинергическое средство, природный растительный алкалоид, в частности, выбранный из группы лобелина, анабазина, цитизина, галантамина или их приемлемых солей, в виде таблеток и капсул. Вспомогательные вещества разработанной пероральной композиции включают порошок целлюлозы, сульфат кальция, коллоидный диоксид кремния и стеарат магния, причем общее содержание порошка целлюлозы и дигидрата сульфата кальция составляет от 64,5 до 97,5% массы лекарственной формы, и по меньшей мере 90% частиц алкалоида являются 100 мкм. Пероральная композиция также содержит по меньшей мере одну биологически активную аминокислоту, выбранную из L-карнитина, триптофана или их комбинации. Пероральная композиция согласно настоящему изобретению обеспечивает равномерное распределение активного вещества в композиции, а также стабильность композиции за счет включенных вспомогательных веществ, выбранных так, чтобы минимально реагировать с алкалоидом с образованием качественно и количественно родственных веществ, приемлемых для фармацевтической композиции. Композиция согласно настоящему изобретению пригодна в лечении зависимости и привыкания к никотину, табачным продуктам и алкоголю.
EA202191589A 2019-04-12 2019-11-28 Пероральная фармацевтическая композиция с растительным алкалоидом для лечения зависимостей EA202191589A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG112910A BG67408B1 (bg) 2019-04-12 2019-04-12 Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
PCT/BG2019/000027 WO2020206511A1 (en) 2019-04-12 2019-11-28 Oral pharmaceutical composition with a plant alkaloid for treatment of dependencies

Publications (1)

Publication Number Publication Date
EA202191589A1 true EA202191589A1 (ru) 2021-07-26

Family

ID=69137657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191589A EA202191589A1 (ru) 2019-04-12 2019-11-28 Пероральная фармацевтическая композиция с растительным алкалоидом для лечения зависимостей

Country Status (13)

Country Link
US (1) US20210275460A1 (ru)
EP (1) EP3952845A1 (ru)
JP (1) JP2022528299A (ru)
KR (1) KR20210153044A (ru)
CN (1) CN113194930A (ru)
AU (1) AU2019440193A1 (ru)
BG (1) BG67408B1 (ru)
BR (1) BR112021011125A2 (ru)
CA (1) CA3126725C (ru)
EA (1) EA202191589A1 (ru)
MX (1) MX2021009885A (ru)
WO (1) WO2020206511A1 (ru)
ZA (1) ZA202105144B (ru)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5414005A (en) * 1993-10-28 1995-05-09 Dynagen, Inc. Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
DE4301782C1 (de) 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
RU2134585C1 (ru) 1997-08-28 1999-08-20 Закрытое акционерное общество "Эвалар" Биологически активная добавка к пище "коррида" для отвыкания от курения
RU2125883C1 (ru) 1997-09-18 1999-02-10 Медведев Виктор Михайлович Сбор "колдунок" лекарственных растений, обладающий успокаивающим и антиникотиновым действием
ES2211215T3 (es) 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. Composicion de galantamina de liberacion controlada.
RU2157704C2 (ru) 1998-12-28 2000-10-20 Алферов Виктор Петрович Антиникотиновое антиалкогольное изделие
US6534527B2 (en) * 2000-06-02 2003-03-18 Phytos, Inc. Edible herbal compositions for relieving nicotine craving
JP3730522B2 (ja) 2000-07-21 2006-01-05 太陽化学株式会社 喫煙欲求抑制組成物
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US20050123502A1 (en) * 2003-10-07 2005-06-09 Chan Shing Y. Nicotine containing oral compositions
BG65536B1 (bg) 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
US20080145422A1 (en) * 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
US20080103111A1 (en) 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
CN101342173A (zh) * 2007-07-13 2009-01-14 和泓生物技术（上海）有限公司 洛贝林在制备治疗神经元凋亡疾病的药物中的应用
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
AU2009332281B2 (en) 2008-12-23 2015-04-30 Tcl Communication Technology Holdings Limited Mobile communication system
CA2781826A1 (en) * 2009-11-26 2011-06-03 Usv Limited Controlled release pharmaceutical compositions of galantamine
ES2688212T3 (es) * 2012-01-20 2018-10-31 Altria Client Services Llc Producto oral
PL220354B1 (pl) * 2012-11-19 2015-10-30 Aflofarm Fabryka Leków Spółka Z Ograniczoną Odpowiedzialnością Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania
CN103284319A (zh) 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
PL408608A1 (pl) * 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
RU2572720C1 (ru) * 2014-07-29 2016-01-20 Дмитрий Евгеньевич Денисов Комплексное антиникотиновое средство
RU2593585C1 (ru) 2015-06-26 2016-08-10 Общество с ограниченной ответственностью "Ритек-Фарма" Способ лечения табакокурения и других форм никотиновой зависимости, а также профилактики рецидивов табакокурения
AU2018306520B2 (en) * 2017-07-24 2022-07-21 Achieve Pharma Uk Limited Cytisine salts
CN107744508A (zh) * 2017-10-14 2018-03-02 威海贯标信息科技有限公司 一种氢溴酸加兰他敏片剂

Also Published As

Publication number Publication date
MX2021009885A (es) 2021-09-14
BG67408B1 (bg) 2022-01-17
CN113194930A (zh) 2021-07-30
CA3126725C (en) 2023-10-17
AU2019440193A1 (en) 2021-06-17
WO2020206511A1 (en) 2020-10-15
BG112910A (bg) 2020-10-30
CA3126725A1 (en) 2020-10-15
EP3952845A1 (en) 2022-02-16
JP2022528299A (ja) 2022-06-10
KR20210153044A (ko) 2021-12-16
US20210275460A1 (en) 2021-09-09
BR112021011125A2 (pt) 2021-11-16
ZA202105144B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
TWI314868B (en) Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient
US20130098377A1 (en) Excipients for nicotine-containing therapeutic compositions
Kichko et al. Bimodal concentration-response of nicotine involves the nicotinic acetylcholine receptor, transient receptor potential vanilloid type 1, and transient receptor potential ankyrin 1 channels in mouse trachea and sensory neurons
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
EP3035939A1 (en) V1a antagonists to treat phase shift sleep disorders
HUP0204202A2 (hu) Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
EA202191589A1 (ru) Пероральная фармацевтическая композиция с растительным алкалоидом для лечения зависимостей
Zaniewska et al. Nicotine dependence—human and animal studies, current pharmacotherapies and future perspectives
WO2018011470A1 (en) A snuff-type composition and method and uses related thereto
RU2572720C1 (ru) Комплексное антиникотиновое средство
JP2019515045A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法
FR2954699A1 (fr) Composition pharmaceutique pour le traitement de la dependance a l'alcool
Mannucci et al. Serotonin mediates beneficial effects of Hypericum perforatum on nicotine withdrawal signs
RU2570374C2 (ru) Твердая лекарственная форма препарата седативного и спазмолитического действия
US20110151035A1 (en) Smoking Cessation Lozenge Containing Tobacco Alkaloid And Silver Salt
US20180104292A1 (en) Synergistic combinations of caffeine, ginkgo biloba and beta-phenylethylamine
WO2012175894A1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
RU2354378C1 (ru) Комбинированный противотуберкулезный препарат
RU2205636C1 (ru) Средство для профилактики вредного воздействия табачного дыма и других продуктов горения
KR101611349B1 (ko) 안정성이 개선된 밀크씨슬 엑스의 제형
IE960511A1 (en) Nicotine-containing homeopathic dilution and its use in¹restoring neuronal function
Panthi FORMULATION AND DEVELOPMENT OF AMISULPRIDE TABLETS AND IT'S COMPARATIVE EVALUATION OF PHYSICAL AND CHEMICAL PARAMETERS BETWEEN ACCELERATED AND REAL TIME STABILITY
Caffeine Asian Journal of Pharmaceutical Technology & Innovation
JP2017525773A (ja) 急性疼痛治療用フィルムコーティング錠剤
BR112017022321B1 (pt) Uso de clonidina e/ou de um derivado de clonidina para o tratamento de astenia e/ou fadiga devido a quimioterapia de agente alquilante